Moody’s downgrades Northeast Ohio Medical University’s rating to ‘Baa2’

Moody’s Investors Service has downgraded the rating on Rootstown-based Northeast Ohio Medical University’s series 2010 and 2011 general receipts bonds to “Baa2,” affecting approximately $40 million.

Advertisement

The downgrade is based on several factors, including increased expense growth and a weakened liquidity profile.

The outlook is negative, reflecting ongoing challenges in terms of NEOMED’s outsized financial leverage.

Moody’s also affirmed the “Baa3” rating on NEOMED’s $36 million of series 2012 student housing revenue bonds. The affirmation is based a number of factors, including improved occupancy rates of the project.

More articles on healthcare finance:
23% of OB units closed in Penn. over last decade
Growing air ambulance industry presents cost, regulation challenges
A.O. Fox Memorial Hospital plans to eliminate labor and delivery services

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Financial Management

Advertisement

Comments are closed.